Scholar Rock (NASDAQ:SRRK) Stock Price Down 5.5% – Time to Sell?

Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) fell 5.5% during trading on Tuesday . The company traded as low as $30.75 and last traded at $30.38. 976,933 shares traded hands during mid-day trading, a decline of 17% from the average session volume of 1,172,661 shares. The stock had previously closed at $32.15.

Analyst Ratings Changes

Separately, Wedbush reissued an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $42.67.

Scholar Rock Trading Down 5.7 %

The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $2.91 billion, a P/E ratio of -13.06 and a beta of 0.56. The business has a 50 day moving average of $36.64 and a 200-day moving average of $33.52.

Insider Transactions at Scholar Rock

In related news, Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the sale, the director now owns 30,319 shares of the company’s stock, valued at approximately $1,043,579.98. This trade represents a 3.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Edward H. Myles sold 12,539 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total value of $554,223.80. Following the transaction, the chief financial officer now directly owns 148,549 shares of the company’s stock, valued at approximately $6,565,865.80. This trade represents a 7.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 299,772 shares of company stock valued at $11,245,798 over the last quarter. Corporate insiders own 19.20% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its position in shares of Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after acquiring an additional 269 shares during the last quarter. Global Retirement Partners LLC boosted its position in Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after purchasing an additional 766 shares during the period. Nisa Investment Advisors LLC grew its stake in Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after buying an additional 1,031 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Scholar Rock in the fourth quarter valued at approximately $85,000. Finally, Amalgamated Bank grew its holdings in Scholar Rock by 30.6% in the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock valued at $114,000 after buying an additional 620 shares in the last quarter. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.